Shanghai RAAS Blood Products' controlling shareholder Haiyingkang has completed its additional purchase and has increased its stake by a total of 1.09%.
Shanghai Laisi (002252.SZ) announced that the company's controlling shareholder Haiyingkang's shareholding plan has been fully implemented. Haiyingkang...
Shanghai RAAS Blood Products (002252.SZ) announced that the shareholding plan of the company's controlling shareholder, Haiying Kang, has been completed. Haiying Kang has accumulated 72.43 million shares of the company through centralized bidding, accounting for 1.09% of the total share capital of the company. The total amount of the shareholding is approximately 497 million yuan (excluding transaction costs).
Related Articles
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
